Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Vaccine shipments to EU slow as Turkey, China put foot on accelerator

Published 01/15/2021, 01:50 PM
Updated 01/15/2021, 02:05 PM
© Reuters. Red Cross mobile COVID-19 vaccination team at a retirement nursery in Dillenburg

By Francesco Guarascio and Andrius Sytas

BRUSSELS/VILNIUS (Reuters) - Some EU nations are receiving fewer than expected doses of coronavirus vaccines as U.S. pharmaceutical firm Pfizer (NYSE:PFE) slows shipments, while Turkey and China race ahead with inoculations to stem surging worldwide infections.

Six EU countries described the delay as unacceptable and said it impacted the credibility of the whole vaccination process.

Spooked by a fast-spreading variant first detected in Britain, governments in Europe have imposed tighter and longer lockdowns and curbs. They are pinning hopes on vaccines being rolled out across the continent.

But even when inoculations start en masse, pressure on health systems is not expected to lift for months, or until most people within a population get the shot.

The vaccine developed by Pfizer with German partner BioNTech started being delivered in the EU at the end of December. U.S. biotech firm Moderna (NASDAQ:MRNA) began delivering its shot this week.

Yet about one third of the 27 EU governments cited "insufficient" doses at a video conference of health ministers on Wednesday, a person who attended the virtual meeting told Reuters.

In a letter sent on Friday, six EU governments asked the European Commission to pressure Pfizer-BioNTech "to ensure stability and transparency of timely (vaccine) deliveries".

"This situation is unacceptable," said the letter, seen by Reuters, signed by the health ministers of Sweden, Denmark, Finland, Lithuania, Latvia and Estonia.

"Not only does it impact the planned vaccination schedules, it also decreases the credibility of the vaccination process."

Commission President Ursula von der Leyen said she had spoken to Pfizer and been reassured that scheduled deliveries will be made in the first quarter of 2021.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Pfizer said there would be a temporary impact on shipments in late January to early February caused by changes to manufacturing processes to boost production.

"Although this will temporarily impact shipments in late January to early February, it will provide a significant increase in doses available for patients in late February and March," Pfizer said in a statement.

TURKEY PUSHES AHEAD

The German health ministry said Pfizer has informed the European Union that it would temporarily reduce deliveries due to construction work at its plant in the Belgian town of Puurs.

Belgium said it expected to receive only around half of the planned doses of the Pfizer vaccine in January. Lithuania said it was told this week its supplies would be halved until mid-February.

Pfizer and BioNTech have two contracts with the EU for the supply of up to 600 million doses this year. They have agreed to deliver 75 million doses in the second quarter and more later in the year.

Moderna has committed to delivering 10 million doses by the end of March and 35 million each in the second and third quarter. Another 80 million doses are also to be delivered this year but without a clear timetable yet.

Turkey, not an EU member, said it had vaccinated more than 600,000 people in the first two days of administering shots developed by China's Sinovac Biotech, among the fastest rollouts in the world.

"We are an experienced country in implementing nationwide inoculation programmes ... We will win the battle with the pandemic together," Health Minister Fahrettin Koca tweeted.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Turkey vaccinated more people on the first day of its programme on Thursday than France had in nearly its first three weeks.

Rising infections are turning up the heat on China to strengthen its own pace of vaccination at home, even as it has been exporting millions of doses of vaccines to countries including Turkey, Indonesia and Brazil.

In the first nine days of January, about 4.5 million doses were given nationwide in China, triple the number given from July to November, Reuters calculations based on official data show. By Jan. 13, more than 10 million doses were given.

Two Chinese firms, Sinovac and Sinopharm, have developed vaccines. Sinopharm shipped more than 10 million doses domestically by Jan 4, while Sinovac delivered more than 7 million doses by Jan 10.

U.S. President-elect Joe Biden will on Friday outline his plan to ramp up vaccinations after an early rollout by the Trump administration which he called "a dismal failure".

Biden has promised to get 100 million vaccine shots into the arms of Americans during his first 100 days in office.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.